Citius Oncology (CTOR) Receivables (2025 - 2026)

Citius Oncology's (CTOR) quarterly Receivables came in at $686235.0 in Q2 2026, down 36.4% quarter-over-quarter from $1.1 million in Q1 2026.

Analysis

Citius Oncology (CTOR) Receivables (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Receivables for 2 consecutive years, with $686235.0 the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	10.23 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	5.90 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	2.13 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	6.57 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	1.93 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	160.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	912.74 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	1.89 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-
10	Citius Oncology	101.41 Mn	101.41 Mn	1.00 Mn	686,235.00

Historic Data

Download Data